ImmuPharma PLC has announced changes to its Board of Directors in order to align with the next phase of the company's progress. Dr. Laurence Reilly has been appointed as Senior independent Non-Executive Director and Chair of the Audit Committee. Dr. Reilly brings extensive experience in managing late-stage clinical programs and has commercial and business development experience. Dr. Sebastien Goudreau has also joined the Board. Dr. Goudreau has been a key contributor to the progression of the company's P140 autoimmune platform. Dr. Sanjeev Pandya has informed the Board that he wishes to step down from his Non-Executive Director position. All Board changes take place with immediate effect.
The CEO of ImmuPharma, Tim McCarthy, expressed his delight at the new appointments and stated that they will bring the essential skills and knowledge required for the next stage of the company's evolution. He also emphasized the company's focus on bringing its two key late-stage P140 clinical assets in Lupus and CIDP through their final clinical trials and to the market. The company will also continue to concentrate on further commercial and partnering opportunities, and the new Board appointments are expected to accelerate these efforts.